Effects of cilostamide and/or forskolin on the meiotic resumption and development competence of growing ovine oocytes selected by brilliant cresyl blue staining

Theriogenology
Nima Azari-DolatabadM H Nasr-Esfahani

Abstract

The relevance of low developmental competence of in vitro-matured oocyte to the incomplete/delayed cytoplasmic maturation, and the heterogeneity of retrieved oocytes is well established in several species. A short phase of prematuration culture was used to allow better oocyte cytoplasmic maturation. The preselection of growing and fully grown oocytes has been proposed to improve developmental competency. This study investigated the effects of phosphodiesterase type 3-specific inhibitor, cilostamide, and adenylate cyclase activator, forskolin, on the resumption of meiosis and developmental competence of growing ovine oocytes selected by brilliant cresyl blue (BCB) staining. Results indicate that cilostamide, forskolin, and their combination significantly (P < 0.05) increased the percentage of growing (BCB-) oocytes maintained at the germinal vesicle stage. However, only forskolin significantly (P < 0.05) increased the yield and quality of blastocysts derived from BCB- oocytes compared with non-BCB-treated oocytes. We conclude that a short prematuration culture with forskolin may improve the in vitro developmental competency of growing oocytes in ovine.

References

Jul 1, 1978·The Journal of Cell Biology·N B GilulaW H Beers
Sep 1, 1988·Biology of Reproduction·M A Sirard, N L First
Apr 1, 1984·Biology of Reproduction·C EkholmS Rosberg
Nov 1, 1995·Journal of Reproduction and Fertility·H AktasM L Leibfried-Rutledge
Feb 3, 2000·Human Reproduction·C AnderieszA O Trounson
May 4, 2002·Molecular and Cellular Endocrinology·Marco ContiAlex Tsafriri
Jun 11, 2002·Theriogenology·E Rodríguez-GonzálezM T Paramio
Jun 20, 2002·Reproduction in Domestic Animals = Zuchthygiene·M MoriT Suzuki
Aug 24, 2002·Science·Lisa M MehlmannLaurinda A Jaffe
May 30, 2003·Biology of Reproduction·Daniela NogueiraJohan Smitz
May 7, 2004·Current Opinion in Obstetrics & Gynecology·Ri-Cheng ChianSeang-Lin Tan
Dec 3, 2005·Reproduction : the Official Journal of the Society for the Study of Fertility·Lisa M Mehlmann
Mar 24, 2006·Reproduction, Fertility, and Development·Christopher G GrupenDavid T Armstrong
Sep 26, 2006·Fertility and Sterility·Marcus W Jurema, Daniela Nogueira
Feb 20, 2007·Annals of the New York Academy of Sciences·Dimitris LoutradisAristidis Antsaklis
Nov 3, 2007·Theriogenology·J S Barry, R V Anthony
Feb 2, 2008·Reproduction : the Official Journal of the Society for the Study of Fertility·Helmut TornerDawit Tesfaye
Apr 29, 2008·The Journal of Reproduction and Development·Hitoshi UshijimaToshio Tajima
Sep 3, 2008·Theriogenology·A ShiraziN Shams-Esfandabadi
Aug 13, 2009·Animal Reproduction Science·Jolanta OpielaLucyna Katska-Ksiazkiewicz
Jun 10, 2011·Molecular Reproduction and Development·F SilvestreE Tosti
Jul 16, 2011·Reproduction : the Official Journal of the Society for the Study of Fertility·Maria Gracia CataláMaria Teresa Paramio
Aug 27, 2011·Journal of Assisted Reproduction and Genetics·Abdollah Mohammadi-SangcheshmehMichael Hoelker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.